Senate Files

Bills

S. 1096 119th Congress

Preserve Access to Affordable Generics and Biosimilars Act

Latest action, Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

8 cosponsors

Sponsored by Amy Klobuchar (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
5 D · 3 R
  • Democrat
  • Republican
  • Independent
8 senators cosponsoring

Referred to: Senate: Judiciary Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

29 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
7 reports
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)
7 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
7 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
THE GIBSON GROUP, LLC
7 reports
BCBSM INC
7 reports
BLUE CROSS AND BLUE SHIELD ASSOCIATION
7 reports
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC
7 reports
BLUE CROSS BLUE SHIELD OF MICHIGAN
7 reports
CAMBIA HEALTH SOLUTIONS
7 reports
GSK (FKA GLAXOSMITHKLINE INC.)
7 reports
GUIDEWELL MUTUAL HOLDING CORPORATION
7 reports
NOVARTIS
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
7 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
CROSSROADS STRATEGIES, LLC
7 reports
TEVA PHARMACEUTICALS USA, INC.
FAEGRE DRINKER BIDDLE & REATH LLP
7 reports
All 25 of 40 clients
ClientLobbying firmReportsReports totalingFromToSenate
AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)7$28.6MQ1 2025Q3 2026yes
AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA)7$70KQ1 2025Q3 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINES7$5.6MQ1 2025Q3 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINESTHE GIBSON GROUP, LLC7$0Q1 2025Q3 2026yes
BCBSM INC7$206KQ1 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION7$8.8MQ1 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC7$810KQ1 2025Q3 2026yes
BLUE CROSS BLUE SHIELD OF MICHIGAN7$1.9MQ1 2025Q3 2026yes
CAMBIA HEALTH SOLUTIONS7$4.6MQ1 2025Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)7$8.9MQ1 2025Q3 2026yes
GUIDEWELL MUTUAL HOLDING CORPORATION7$40KQ1 2025Q3 2026yes
NOVARTIS7$14.0MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA7$64.5MQ1 2025Q3 2026yes
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICACROSSROADS STRATEGIES, LLC7$0Q1 2025Q3 2026yes
TEVA PHARMACEUTICALS USA, INC.FAEGRE DRINKER BIDDLE & REATH LLP7$0Q1 2025Q3 2026yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.7$630KQ1 2025Q3 2026yes
BIOTECHNOLOGY INNOVATION ORGANIZATION6$10.3MQ1 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD OF KANSAS INC6$60KQ1 2025Q3 2026yes
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)WHITMER & WORRALL, LLC6$300KQ1 2025Q2 2026yes
TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY)TIBER CREEK GROUP6$480KQ4 2025Q3 2026yes
VIATRIS (MYLAN, INC)S-3 GROUP6$360KQ4 2025Q3 2026yes
CONSERVATIVES FOR PROPERTY RIGHTSELITE STRATEGIC SERVICES4$163KQ4 2025Q1 2026yes
T1INTERNATIONAL USA4$0Q1 2025Q1 2026yes
AARP3$15.6MQ1 2025Q1 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINESTWINLOGIC STRATEGIES, LLP3$0Q1 2026Q3 2026yes